Kinase modulation, and indications therefor

Patent metadata

Field	Value
Publication number	US-9814714-B2
Application number	US-201615160729-A
Country	US
Kind code	B2
Filing date	May 20, 2016
Priority date	May 22, 2015
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.

First claim

What is claimed is:

1. A method of treating or inhibiting a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF, in a subject suffering from or at risk for a said disease or condition, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt, isomer, tautomer or deuterated form thereof.

2. The method according to claim 1 , wherein the non-activation of the MAPK pathway or non-inducement of expression of MAPK pathway genes in cells harboring wild-type BRAF comprises inhibition of phosphor-ERK (pERK) in BRAF wild-type cells.

3. The method according to claim 1 , wherein the non-activation of the MAPK pathway or non-inducement of expression of the MAPK pathway comprises inhibition of pERK and pMEK in BRAF wild-type cells.

4. The method according to claim 1 , wherein the non-activation of the MAPK pathway or non-inducement of expression of MAPK pathway genes in cells harboring wild-type BRAF inhibits stimulation of cell growth.

5. The method according to claim 1 , wherein the non-activation of the MAPK pathway or non-inducement of expression of MAPK pathway genes in cells harboring wild-type BRAF inhibits stimulation of skin neoplasms.

6. The method according to claim 1 , wherein the therapeutically effective amount of Formula I is administered in a pharmaceutical composition further comprising a pharmaceutically acceptable excipient or carrier.

7. The method according to claim 1 , wherein the therapeutically effective amount of Formula I is administered in a pharmaceutical composition further comprising another therapeutic agent.

8. The method according to claim 1 , wherein the BRAF V600 mutation or BRAF fusion mutation related disease or condition is melanoma, colorectal cancer, papillary thyroid cancer, anaplastic thyroid cancer, ovarian cancer, non-small-cell lung cancer, gastric cancer, cholangiocarcinoma, Barrett's esophageal cancer, head and neck cancer, hepatocellular carcinoma, Langerhan's cell histiocytosis, gastrointestinal stromal cell tumours, multiple myeloma, pediatric astrocytomas, pleomorphic xanthoastrocytomas, chronic myeloid leukemia, acute myelomonocytic leukemia, biphenotypic B myelomonocytic leukemia, acute myeloid leukemia, hairy cell leukemia, nevi, Erdheim-Chester disease, malignant peripheral nerve sheath tumor, inflammatory and autoimmune disease, tenosynovial giant cell tumor, pigmented villonodular synovitis, giant cell tumor of tendon sheath, giant cell tumor of bone, cervical cancer, endometrial cancer, germ cell tumors, prostate cancer, bladder cancer, myopericytoma, metanephric adenoma, pancreatic neoplasms, neuroendocrine tumors, endocrine tumors, adrenal tumors, adrenal medullary tumors, cystadenocarcinoma of the parotid, glioblastoma multiforme, bile duct cancer including bile duct adenoma, B-cell chronic lymphoproliferative disorder, dendritic cell sarcomas, histiocytic sarcomas, or lymphoma.

9. The method according to claim 1 , wherein the BRAF V600 mutation or BRAF fusion mutation related disease or condition is hepatocellular carcinoma, Langerhan's cell histiocytosis, gastrointestinal stromal cell tumours, multiple myeloma, pediatric astrocytomas, pleomorphic xanthoastrocytomas, chronic myeloid leukemia, acute myelomonocytic leukemia, biphenotypic B myelomonocytic leukemia, acute myeloid leukemia, hairy cell leukemia, or nevi.

10. The method according to claim 1 , wherein the BRAF V600 mutation or BRAF fusion mutation related disease or condition is melanoma, colorectal cancer, papillary thyroid cancer, anaplastic thyroid cancer, ovarian cancer, non-small-cell lung cancer, gastric cancer, cholangiocarcinoma, Barrett's esophageal cancer, or head and neck cancer.

11. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is Erdheim-Chester disease.

12. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is melanoma.

13. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is metastatic melanoma.

14. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is colorectal cancer.

15. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is papillary thyroid cancer.

16. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is anaplastic thyroid cancer.

17. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is ovarian cancer.

18. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is non-small-cell lung cancer.

19. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is gastric cancer.

20. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is Langerhan's cell histiocytosis.

21. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is acute myeloid leukemia.

22. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is multiple myeloma.

23. The method according to claim 1 , wherein the BRAF V600 mutation related disease or condition is malignant peripheral nerve sheath tumor.

24. The method according to claim 1 , wherein the BRAF fusion mutation related disease or condition is pediatric astrocytomas.

25. The method according to claim 1 , wherein the BRAF V600 mutation is one or more mutations selected from the group consisting of V600E, V600K, V600D, V600A, V600G, V600M, and V600R.

26. The method according to claim 1 , wherein the BRAF V600 mutation comprises a V600E mutation and a V600K mutation.

27. The method according to claim 1 , wherein the BRAF V600 mutation comprises a V600E mutation.

28. The method according to claim 1 , further comprising administering to said subject one or more of the following agents: adozelesin, altretamine, bendamustine, bizelesin, busulfan, carboplatin, carboquone, carmofur, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, etoglucid, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mannosulfan, mechlorethamine, melphalan, mitobronitol, nedaplatin, nimustine, oxaliplatin, piposulfan, prednimustine, procarbazine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, thiotepa, treosulfan, triaziquone, triethylenemelamine, triplatin tetranitrate, trofosphamide, uramustine, aclarubicin, amrubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, idarubicin, menogaril, mitomycin, neocarzinostatin, pentostatin, pirarubicin, plicamycin, valrubicin, zorubicin, aminopterin, azacitidine, azathioprine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabinc, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, azathioprine, raltitrexed, tegafur-uracil, thioguanine, trimethoprim, trimetrexate, vidarabine, alemtuzumab, pembrolizumab, nivolumab,

Assignees

• Plexxikon Inc

Inventors

• Ibrahim Prabha N
• Zhang Chao
• Spevak Wayne
• Zhang Jiazhong
• Wu Guoxian
• Lin Jack
• Cho Hanna
• Nespi Marika
• Shi Songyuan
• Ewing Todd
• Zhang Ying
• Bollag Gideon

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title